Helus Pharma Announces Topline Results From Its APPROACH Phase 3 Study Evaluating HLP003 For Adults With Major Depressive Disorder; 7.6 Point Placebo-Adjusted Change From Baseline At Week 6 For The Primary Endpoint; Durable Effect Maintained Through...

Benzinga
Abrir en Benzinga